A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth
factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic
cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient
medicine is available for acromegalic cardiomyopathy until now and there were limited
studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients
and independent of blood glucose control. We planed to evaluate the structure of heart by MRI
before and after 6 months treatment with empagliflozin in acromegalic patients to investigate
the effect of empagliflozin on acromegalic cardiomyopathy.